The AHFIRM trial did not demonstrate a beneficial effect of larsucosterol on 90-day mortality or the need for liver transplant among patients with severe alcohol-associated hepatitis, or AH, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback